1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

IPF marketers push for more patients

 
• By Lisa LaMotta

With both Esbriet and Ofev gaining approval on the same day, Roche's Genentech and Boehringer Ingelheim have been working to differentiate their respective drugs in the idiopathic pulmonary fibrosis market. Recent spates of data released at the American Thoracic Society annual meeting in Denver could help expand the patient populations for the two therapies.

Both Roche's Esbriet (pirfenidone) and Boehringer's Ofev (nintedanib) were approved by FDA on 15 October and the companies have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

More from Therapy Areas